Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Idalopirdine TQT study in healthy men
NCT02436486Phase 1Completed
- Sponsor
- Lundbeck
- Start
- May 2015
- Primary completion
- Aug 2015
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of Idalopirdine in Alzheimer's disease (AD) (4 arms), sponsored by Lundbeck. Primary endpoint: Change from pre-dose baseline in the QT interval (ΔQTcF) at 24 hours. Started May 2015; status: completed.
02
Drugs
Idalopirdine
03
Conditions
Alzheimer's disease (AD)
Beyond the preview
Go deeper on NCT02436486.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02436486.